A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, RANDOMIZED, 24-WEEK, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF ROCATINLIMAB (AMG 451) MONOTHERAPY IN ADULT SUBJECTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD) (ROCKET-HORIZON)

Intervention/treatment:
AMG 451 (ROCATINLIMAB)
Medical condition:
ATOPIC DERMATITIS
Protocol code:
20210143
Control number:
268845
Status:
Closed
Approved:
November 17, 2022
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT05651711
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 100 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Study Director
Organization
Amgen Inc.
Phone:
866-572-6436
Sponsor
AMGEN CANADA INC

Locations

Alberta

Beacon Dermatology
Calgary, Alberta, T3E 0B2

British Columbia

Doctor Chih-Ho Hong Medical Incorporated
Surrey, British Columbia, V3R 6A7

Ontario

Kingsway Clinical Research
Etobicoke, Ontario, M8X 1Y9
Lynderm Research Inc
Markham, Ontario, L3P 1X3
Research Toronto
Toronto, Ontario, M4W 2N4
SKiN Centre for Dermatology
Peterborough, Ontario, K9J 5K2
The Centre for Clinical Trials Inc
Oakville, Ontario, L6J 7W5
The Centre for Dermatology
Richmond Hill, Ontario, L4B 1A5
XLR8 Medical Research, Incorporated
Windsor, Ontario, N8T 1E6

Quebec

Centre de Recherche Dermatologique du Quebec Metropolitain
Québec, Quebec, G1V 4X7
Clinique Dermatologique de Sherbrooke
Sherbrooke, Quebec, J1G 1X9

Results

See the results from the trial NCT05651711. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?